Comparing the lifetime risks of TNF-a inhibitor use in patients with severe psoriasis to common benchmarks of risk - 07/03/12
Edidong Ntuen, MD, MS, Wake Forest University School of Medicine, Winston Salem, NC, United States; Ayub Qureshi, MBBS, Wake Forest University School of Medicine, Winston Salem, NC, United States; Isha Patel, MS, Center of Medication Usage, Policy and Economics, University of Michigan, Ann Arbor, MI, United States; Jenna O'Neill, MD, Wake Forest University School of Medicine, Winston Salem, NC, United States; Rajesh Balkrishnan, PhD, Center for Medication Use, Policy and Economics; University of Michigan, Ann Arbor, MI, United States; Steve Feldman, MD, PhD, Wake Forest University School of Medicine, Winston Salem, NC, United States; Tushar Dabade, MD, Wake Forest University School of Medicine, Winston Salem, NC, United States
Le texte complet de cet article est disponible en PDF.| Commercial support: The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P. |
Vol 66 - N° 4S1
P. AB188 - avril 2012 Retour au numéro
Article précédent
- Combined clinical, videodermatoscopic, and ultrasound evaluation of psoriasis treated with biologics provides objective therapeutic response
- Comparison of benefit–risk profiles with adalimumab versus etanercept treatment for moderate to severe psoriasis, stratified by weight
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?